Phaseline

Companies › Ascendo Biotechnology

Ascendo Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASD141–Phase 1Metastatic Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06235437ASD141Phase 1Metastatic Solid TumorOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.